SHMT2 and colonic neoplasm: In colon cancer, acetylation of Lys95 in SHMT2 disrupted its tetramer structure and inhibited its enzymatic activity; this acetylation also promoted SHMT2 degradation through the ubiquitin‐lysosome pathway.